Giannakakou, Paraskevi

Publications

Sort by

Co-Author Network

selected publications

AR-V7 exhibits non-canonical mechanisms of nuclear import and chromatin engagement in castrate-resistant prostate cancer. eLife. 2022 Academic Article GET IT
Times cited: 4
CLIP-170S is a microtubule +TIP variant that confers resistance to taxanes by impairing drug-target engagement. Developmental cell. 2021 Academic Article GET IT
Times cited: 4
Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage. Communications biology. 2021 Academic Article GET IT
Times cited: 3
Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 11
Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer. Molecular cancer research : MCR. 2021 Academic Article GET IT
Times cited: 10
Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer. JCO precision oncology. 2020 Academic Article GET IT
Times cited: 40
Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 6
Taxane resistance in prostate cancer is mediated by decreased drug-target engagement. The Journal of clinical investigation. 2020 Academic Article GET IT
Times cited: 22
Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 14
Quantitative analysis of taxane drug target engagement of microtubules in circulating tumor cells from metastatic castration resistant prostate cancer patients treated with CRXL301, a nanoparticle of docetaxel. Cancer drug resistance (Alhambra, Calif.). 2020 Academic Article GET IT
Times cited: 141
A Bayesian machine learning approach for drug target identification using diverse data types. Nature communications. 2019 Academic Article GET IT
Times cited: 99
Clinical Significance of AR-V567es in Prostate Cancer-Response. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Letter GET IT
Times cited: 1
Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer. PloS one. 2019 Academic Article GET IT
Times cited: 10
Androgen receptor nuclear localization correlates with AR-V7 mRNA expression in circulating tumor cells (CTCs) from metastatic castration resistance prostate cancer patients. Physical biology. 2019 Academic Article GET IT
Times cited: 10
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 218
Expression of AR-V7 and ARv^567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 74
Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation. Nature cell biology. 2018 Academic Article GET IT
Times cited: 887
Using circulating tumor cells to advance precision medicine in prostate cancer. Journal of cancer metastasis and treatment. 2017 Academic Article GET IT
Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Academic Article GET IT
Times cited: 55
Widespread Mitotic Bookmarking by Histone Marks and Transcription Factors in Pluripotent Stem Cells. Cell reports. 2017 Academic Article GET IT
Times cited: 78
A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity. Cancer cell. 2016 Academic Article GET IT
Times cited: 26
A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity. Cancer cell. 2016 Article GET IT
Times cited: 26
A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity. Cancer cell. 2016 Academic Article GET IT
Times cited: 148
CANCER. Cancer therapies that are gone with the Wnt. Science (New York, N.Y.). 2015 Comment GET IT
Times cited: 4
Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy. Critical reviews in oncology/hematology. 2015 Review GET IT
Times cited: 37
β-1 tubulin R307H SNP alters microtubule dynamics and affects severity of a hereditary thrombocytopenia. Journal of thrombosis and haemostasis : JTH. 2015 Academic Article GET IT
Times cited: 18
ERG induces taxane resistance in castration-resistant prostate cancer. Nature communications. 2014 Academic Article GET IT
Times cited: 91
Decade in review-funding in cancer research: National Cancer Institute awards-a work in progress. Nature reviews. Clinical oncology. 2014 Article GET IT
Times cited: 2
Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential. Molecular diagnosis & therapy. 2014 Academic Article GET IT
Times cited: 39
RABbing cancer the wrong way. Proceedings of the National Academy of Sciences of the United States of America. 2014 Comment GET IT
Times cited: 2
NAD+ and SIRT3 control microtubule dynamics and reduce susceptibility to antimicrotubule agents. Proceedings of the National Academy of Sciences of the United States of America. 2014 Academic Article GET IT
Times cited: 29
Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer research. 2014 Academic Article GET IT
Times cited: 193
Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flow. PloS one. 2013 Academic Article GET IT
Times cited: 34
Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device. Lab on a chip. 2013 Academic Article GET IT
Times cited: 81
BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling. Oncogene. 2013 Academic Article GET IT
Times cited: 45
The beta 1 tubulin R307H single nucleotide polymorphism is associated with treatment failures in immune thrombocytopenia (ITP). British journal of haematology. 2012 Academic Article GET IT
Times cited: 22
Isolation and characterization of circulating tumor cells in prostate cancer. Frontiers in oncology. 2012 Academic Article GET IT
Times cited: 72
Integrating image analysis algorithms in a web interface for the quantification of microtubule dynamics. International journal of computational biology and drug design. 2012 Academic Article GET IT
Androgen receptor on the move: boarding the microtubule expressway to the nucleus. Cancer research. 2012 Review GET IT
Times cited: 123
Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PloS one. 2012 Academic Article GET IT
Times cited: 181
Microtubules regulate hypoxia-inducible factor-1α protein trafficking and activity: implications for taxane therapy. The Journal of biological chemistry. 2012 Academic Article GET IT
Times cited: 54
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer research. 2011 Academic Article GET IT
Times cited: 356
A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model. ACS nano. 2011 Academic Article GET IT
Times cited: 131
Peloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes. Molecular cancer therapeutics. 2011 Academic Article GET IT
Times cited: 37
Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies. Cancer. 2011 Academic Article GET IT
Times cited: 16
Microtubule disruption targets HIF-1alpha mRNA to cytoplasmic P-bodies for translational repression. The Journal of cell biology. 2011 Academic Article GET IT
Times cited: 76
Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer. Urologic oncology. 2010 Academic Article GET IT
Times cited: 13
CENP-E checks in microtubule-drug resistance. Cell cycle (Georgetown, Tex.). 2010 Comment GET IT
Times cited: 4
The hematopoietic-specific beta1-tubulin is naturally resistant to 2-methoxyestradiol and protects patients from drug-induced myelosuppression. Cell cycle (Georgetown, Tex.). 2009 Academic Article GET IT
Times cited: 15
Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab on a chip. 2009 Academic Article GET IT
Times cited: 317
HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors. ACS nano. 2009 Academic Article GET IT
Times cited: 159
The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner. The Journal of biological chemistry. 2009 Academic Article GET IT
Times cited: 33
Syntheses and biological activities of novel 2-methoxyestradiol analogs, 2-fluoroethoxyestradiol and 2-fluoropropanoxyestradiol, and a radiosynthesis of 2-[(18)F]fluoroethoxyestradiol for positron emission tomography. Nuclear medicine and biology. 2008 Academic Article GET IT
Times cited: 5
EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1. Cell cycle (Georgetown, Tex.). 2008 Academic Article GET IT
Times cited: 92
Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function. Molecular cancer therapeutics. 2007 Academic Article GET IT
Times cited: 60
Evaluation of the tubulin-bound paclitaxel conformation: synthesis, biology, and SAR studies of C-4 to C-3' bridged paclitaxel analogues. Journal of medicinal chemistry. 2007 Academic Article GET IT
Times cited: 66
Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer research. 2006 Academic Article GET IT
Times cited: 76
Farnesyltransferase inhibitors reverse taxane resistance. Cancer research. 2006 Academic Article GET IT
Times cited: 33
Automatic microtubule tracking for QD-based in vivo cell imaging and drug efficacy study. Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference. 2006 Academic Article GET IT
Times cited: 2
Molecular design and chemical synthesis of a highly potent epothilone. ChemMedChem. 2006 Academic Article GET IT
Times cited: 45
Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele. Cell cycle (Georgetown, Tex.). 2005 Academic Article GET IT
Times cited: 37
Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the paclitaxel site predicts cytotoxicity. Chemistry & biology. 2005 Academic Article GET IT
Times cited: 196
Discovery of a biologically active thiostrepton fragment. Journal of the American Chemical Society. 2005 Academic Article GET IT
Times cited: 60
beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells. Cancer research. 2005 Academic Article GET IT
Times cited: 36
Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer research. 2005 Academic Article GET IT
Times cited: 165
Cyclostreptin (FR182877), an antitumor tubulin-polymerizing agent deficient in enhancing tubulin assembly despite its high affinity for the taxoid site. Biochemistry. 2005 Academic Article GET IT
Times cited: 47
Accumulation of hypoxia-inducible factor-1alpha is limited by transcription-dependent depletion. Oncogene. 2005 Academic Article GET IT
Times cited: 54
The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer research. 2005 Academic Article GET IT
Times cited: 96
Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer research. 2005 Academic Article GET IT
Times cited: 150
Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells. The Journal of biological chemistry. 2005 Academic Article GET IT
Times cited: 156
Computer assisted analysis of microtubule dynamics in living cells. Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference. 2005 Academic Article GET IT
Targeting microtubules for cancer chemotherapy. Current medicinal chemistry. Anti-cancer agents. 2005 Review GET IT
Times cited: 408
Survivin deregulation in beta-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol. Cancer research. 2004 Academic Article GET IT
Times cited: 40
Chemistry and biology of diazonamide A: second total synthesis and biological investigations. Journal of the American Chemical Society. 2004 Academic Article GET IT
Times cited: 154
Studies toward diazonamide A: development of a hetero-pinacol macrocyclization cascade for the construction of the bis-macrocyclic framework of the originally proposed structure. Journal of the American Chemical Society. 2004 Academic Article GET IT
Times cited: 59
Exploitation of the HIF axis for cancer therapy. Cancer biology & therapy. 2004 Review GET IT
Times cited: 33
Interaction of epothilone analogs with the paclitaxel binding site: relationship between binding affinity, microtubule stabilization, and cytotoxicity. Chemistry & biology. 2004 Academic Article GET IT
Times cited: 115
Total synthesis of apoptolidin: completion of the synthesis and analogue synthesis and evaluation. Journal of the American Chemical Society. 2003 Academic Article GET IT
Times cited: 96
Total synthesis and biological evaluation of (-)apicularen A and analogues thereof. Chemistry (Weinheim an der Bergstrasse, Germany). 2003 Academic Article GET IT
Times cited: 56
The importance of p53 location: nuclear or cytoplasmic zip code?. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. 2003 Review GET IT
Times cited: 182
Design, synthesis, and biological properties of highly potent epothilone B analogues. Angewandte Chemie (International ed. in English). 2003 Academic Article GET IT
Times cited: 68
2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer cell. 2003 Academic Article GET IT
Times cited: 669
Paclitaxel-resistant human ovarian cancer cells undergo c-Jun NH2-terminal kinase-mediated apoptosis in response to noscapine. The Journal of biological chemistry. 2002 Academic Article GET IT
Times cited: 129
Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics. Proceedings of the National Academy of Sciences of the United States of America. 2002 Academic Article GET IT
Times cited: 182
The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. Biochemistry. 2002 Academic Article GET IT
Times cited: 229
Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism. Biochemical pharmacology. 2001 Academic Article GET IT
Times cited: 48
Chemical synthesis and biological evaluation of cis- and trans-12,13-cyclopropyl and 12,13-cyclobutyl epothilones and related pyridine side chain analogues. Journal of the American Chemical Society. 2001 Academic Article GET IT
Times cited: 88
Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents. Clinical cancer research : an official journal of the American Association for Cancer Research. 2001 Academic Article GET IT
Times cited: 87
Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene. 2001 Academic Article GET IT
Times cited: 216
Inhibition of HIF-1- and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions. Carcinogenesis. 2001 Academic Article GET IT
Times cited: 30
Synthesis and biological evaluation of 12,13-cyclopropyl and 12,13-cyclobutyl epothilones. Chembiochem : a European journal of chemical biology. 2001 Academic Article GET IT
Times cited: 37
p53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nature cell biology. 2000 Academic Article GET IT
Times cited: 309
Reply. Trends in pharmacological sciences. 2000 Academic Article GET IT
Chemical synthesis and biological properties of pyridine epothilones. Chemistry & biology. 2000 Academic Article GET IT
Times cited: 140
Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. Oncogene. 2000 Academic Article GET IT
Times cited: 65
Discodermolide: just another microtubule-stabilizing agent? No! A lesson in synergy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000 Editorial Article GET IT
Times cited: 28
A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 2000 Academic Article GET IT
Times cited: 475
Tubulin/microtubules: still a promising target for new chemotherapeutic agents. Journal of the National Cancer Institute. 2000 Editorial Article GET IT
Times cited: 98
Regulation of apoptosis in myeloid cells by interferon consensus sequence-binding protein. The Journal of experimental medicine. 1999 Academic Article GET IT
Times cited: 102
Synthesis and biological evaluation of 2-acyl analogues of paclitaxel (Taxol). Journal of medicinal chemistry. 1998 Academic Article GET IT
Times cited: 74
Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. The Journal of clinical endocrinology and metabolism. 1998 Academic Article GET IT
Times cited: 90
Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. The Journal of biological chemistry. 1998 Academic Article GET IT
Times cited: 368
Combinations of paclitaxel and vinblastine and their effects on tubulin polymerization and cellular cytotoxicity: characterization of a synergistic schedule. International journal of cancer. 1998 Academic Article GET IT
Times cited: 54
The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Molecular pharmacology. 1997 Academic Article GET IT
Times cited: 262
Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. The Journal of biological chemistry. 1997 Academic Article GET IT
Times cited: 664
Synthesis of epothilones A and B in solid and solution phase. Nature. 1997 Academic Article GET IT
Times cited: 393
Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). The Journal of biological chemistry. 1997 Academic Article GET IT
Times cited: 512
Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer research. 1997 Academic Article GET IT
Times cited: 404
Tubulin from paclitaxel-resistant cells as a probe for novel antimicrotubule agents. Cancer chemotherapy and pharmacology. 1997 Academic Article GET IT
Times cited: 12
Effect of calcium channel blockers on the action of various antitumour agents in the yeast Saccharomyces cerevisiae. The Journal of applied bacteriology. 1996 Academic Article GET IT
Times cited: 12
Brain-derived neurotrophic factor protects neuroblastoma cells from vinblastine toxicity. Cancer research. 1996 Academic Article GET IT
Times cited: 63

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

A novel, short isoform of the +TIP microtubule (MT) binding protein CLIP170 confers taxane resistance by obstructing the MT pore. awarded by National Cancer Institute Principal Investigator 2018 - 2024
Nanostructure-Enhanced Infra-Red Absorption Spectroscopy (NEIRAS) assay to improve Prognosis and Personalized Therapy of Drug-resistant Prostate Cancers awarded by National Institute of General Medical Sciences Principal Investigator 2023 - 2023
Development of Selective Small Molecule AR-V7 Inhibitors for Prostate Cancer Treatment awarded by Daedalus Fund for Innovation (Weill Cornell) Principal Investigator 2021 - 2023
Transferrin Receptor Identifies a Comprehensive pool of Circulating Tumor Cells with unique molecular features from metastatic Prostate Cancer Patients awarded by United States Department of Defense Principal Investigator 2019 - 2023
Molecular and Translational Oncology Research awarded by National Cancer Institute Principal Investigator 2017 - 2023

Heating cold prostate tumors with PSMA-targeted alpha therapy and pembrolizumab awarded by United States Department of Defense Co-Investigator 2020 - 2024

Weill Cornell Medicine (WCM) SPORE in Prostate Cancer awarded by National Cancer Institute Key Personnel 2017 - 2023

Automated Rapid Dual-Extraction of DNA and RNA from Single Cells in Microplates awarded by National Cancer Institute Principal Investigator Subaward 2022 - 2023

more ...

less ...

Background

education and training

Ph.D., Athens University Medical School (Greece) 1997

Contact

full name

Paraskevi Giannakakou

primary email

pag2015@med.cornell.edu

VIVO Weill Cornell Medical College

Paraskevi Giannakakou Professor of Pharmacology in Medicine

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email